How New Atumelnant and PALSONIFY Data At Crinetics Pharmaceuticals (CRNX) Has Changed Its Investment Story

• In mid-June 2026, Crinetics Pharmaceuticals reported new clinical data at ENDO 2026 showing that oral atumelnant improved key biomarkers in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, while PALSONIFY (paltusotine) maintained biochemical control, symptom stability and generally favorable tolerability in acromegaly over periods of up to two years.
• Together, these results highlight Crinetics’ progress in building an endocrinology franchise that combines an already approved oral acromegaly therapy with a late-stage ACTH receptor antagonist candidate targeting additional hormone-driven disorders.
• We’ll now examine how atumelnant’s Phase 2 data, alongside PALSONIFY’s long-term acromegaly profile, may influence Crinetics’ existing investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Crinetics Pharmaceuticals Investment Narrative Recap

To own Crinetics today, you need to believe that PALSONIFY can scale from an early acromegaly launch into a meaningful commercial product while atumelnant matures into a second pillar in ACTH driven diseases. The ENDO 2026 data support that vision scientifically, but the most important near term catalyst remains PALSONIFY prescription growth versus rising operating spend, and the key risk is that uptake and payer behavior do not keep pace with the company’s cash burn.

The ENDO 2026 PATHFNDR open label extension results are particularly relevant here, as they extend PALSONIFY’s dataset to roughly two years of treatment with stable IGF 1 control, symptom scores and no new safety signals. For investors watching real world launch metrics, this kind of durability evidence can be an important input into endocrinologists’ willingness to switch patients from injectables, which in turn feeds into how credible consensus revenue expectations appear.

Yet investors should also be aware that if PALSONIFY’s launch underperforms or payer terms tighten, the current cash runway and dilution risk story could look very different…

Read the full narrative on Crinetics Pharmaceuticals (it’s free!)

Crinetics Pharmaceuticals’ narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This requires 566.4% yearly revenue growth and an earnings increase of about $517.9 million from -$423.1 million today.

Uncover how Crinetics Pharmaceuticals’ forecasts yield a $82.43 fair value, a 135% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$534,200,000 by 2028, and assuming PALSONIFY’s payer support holds up, which is a far more bullish view than consensus and could shift again as investors weigh these ENDO 2026 results against the risk that payers later tighten prior authorizations or introduce tougher step edits.

Explore 4 other fair value estimates on Crinetics Pharmaceuticals – why the stock might be a potential multi-bagger!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Contemplating Other Strategies?

Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com